Mr. Mucus helps Reckitt dominate cough-and-cold space

What's the key to landing your brand on the leaderboard of cough-and-cold meds? Mr. Mucus, apparently. The Reckitt Benckiser spokes-character has propelled Mucinex to three of the top four slots on a new list of preferred OTC products, according to online data-analysis company Treato. More from FiercePharmaMarketing

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.